Optimization of new generation therapy for NK/T-cell lymphoma in East Asia
Project/Area Number |
17K09924
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Mie University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
鈴木 律朗 島根大学, 学術研究院医学・看護学系, 准教授 (20280810)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | NK/T細胞リンパ腫 / 新世代治療 / 多施設共同研究 / 国際情報交換 / RT-2/3DeVIC療法 / SMILE療法 / 内科 / 東アジア / 予後予測 / 国際共同研究 |
Outline of Final Research Achievements |
We conducted a retrospective study including patients with extranodal natural killer/T-cell lymphoma, nasal type (ENKL) diagnosed between 2000 and 2013 in 31 hospitals in Japan in part in collaborating with Korean researchers. Approximately 25% of patients with localized nasal ENKL experienced progression of disease within 24 months, regardless of treatment regimens. Most patients with extranasal ENKL did not receive new generation therapy due to impaired organ function or poor general condition. The long-term efficacy and safety of RT-DeVIC for newly-diagnosed localized nasal ENKL were confirmed with a median follow-up of 7.9 years.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究により、日本国内におけるENKL新世代治療の実態がさらに明らかにされた。早期増悪や鼻外発症など、新世代治療によっても満たされていない医療ニーズを持つ患者集団の同定は、今後の治療開発の基盤となるものである。依頼により執筆した複数の総説は国内外での治療アプローチを偏りなくレビューしており、すでに多く閲覧および引用されていることから、当初治療コンセンサスレポートの作成で意図した役割を果たしつつある。
|
Report
(4 results)
Research Products
(23 results)
-
-
-
-
[Journal Article] Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin2019
Author(s)
Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N
-
Journal Title
Annals of Hematology
Volume: 98
Issue: 7
Pages: 1647-1655
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Early disease progression in patients with localized NK/T-cell lymphoma treated with concurrent chemoradiotherapy.2018
Author(s)
Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, Miyazaki K, Terui Y, Kubota N, Maeda T, Kobayashi Y, Amaki J, Soejima T, Saito B, Shimoda E, Fukuhara N, Tsukamoto N, Shimada K, Choi I, Utsumi T, Ejima Y, Kim WS, Katayama N.
-
Journal Title
Cancer Sci
Volume: -
Issue: 6
Pages: 2056-2062
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
[Presentation] CLINICAL OUTCOMES AND DIAGNOSIS-TO-TREATMENT INTERVAL IN PATIENTS WITH NK/T-CELL LYMPHOMA: 7-YEAR FOLLOW-UP OF THE NKEA STUDY2019
Author(s)
Yamaguchi M, Suzuki R, Oguchi M, Miyazaki K, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Katayama N
Organizer
15-ICML International Conference on Malignant Lymphoma
Related Report
Int'l Joint Research
-
[Presentation] Seven-year follow-up of 101 patients with advanced NK/T-cell lymphoma: NKEA study2019
Author(s)
Miyazaki K, Suzuki R, Yamaguchi M, Amaki J, Sekiguchi N, Takizawa J, Ando T, Wada H, Masaki Y, Kameoka Y, Murayama T, Asano N, Oguchi M, Katayama N
Organizer
The 10th JSH International Symposium 2019 in Ise-Shima
Related Report
Int'l Joint Research
-
-
-
-
-
[Presentation] Incidence and risk factors of central nervous system relapse in localized extranodal NK/T-cell lymphoma, nasal type: an analysis of NKEA study2018
Author(s)
Miyazaki K, Taguchi S, Oguchi M, Suzuki R, Asano N, Terui Y, Kubota N, Saito Y, Maeda T, Itasaka S, Kobayashi Y, Itami J, Amaki J, Akiba T, Murayama T, Ii N, Soejima T, Yamaguchi M, Katayama N
Organizer
2018 ASH Annual Meeting
Related Report
Int'l Joint Research
-
[Presentation] Early disease progression in patients (pts) with newly diagnosed localized nasal extranodal NK/T-cell lymphoma, nasal type (ENKL) treated with radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC)2017
Author(s)
Yamaguchi M, Suzuki R, Oguchi M, Asano N, Miyazaki K, Terui Y, Kubota N, Maeda T, Kobayashi Y, Amaki J, Soejima T, Saito B, Shimoda E, Fukuhara N, Tsukamoto N, Shimada K, Choi I, Utsumi T, Ejima Y, Katayama N, NKEA project.
Organizer
2017 ASCO Annual Meeting
Related Report
Int'l Joint Research
-
-
-
[Presentation] Improved prognosis of extranodal NK/T-cell lymphoma, nasal type (ENKL) of nasal origin but not extranasal origin: an analysis of NKEA study2017
Author(s)
Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Inagaki S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Asano N, Oguchi M, Katayama N.
Organizer
2017 ASH Annual Meeting
Related Report
Int'l Joint Research
-
-